Todos Med Ltd (TOMDF)

[delerious1]

So if "the recent studies suggest the virus is poised to develop resistance—a fate that befalls many antiviral drugs. Two preprints posted on bioRxiv on 7 June, for example, show that SARS-coV-2 grown in the lab quickly gains the ability to avoid nirmatrelvir’s attack. "

Research is showing that continued use of nirmatrelvir could allow the virus time to mutate and become resistant to nirmatrelvir, Pfizer's 3ClL protease inhibitor, which is part of Paxlovid.

If Covid can do this to Pfizer's 3CL protease inhibitor Nirmatrelvir....how dose it fare against Tollovid/r's 3CL Protease Inhibitor ?